Safety of prolonged, repeated administration of a pulmonary formulation of tissue plasminogen activator in mice
- 30 April 2010
- journal article
- Published by Elsevier BV in Pulmonary Pharmacology & Therapeutics
- Vol. 23 (2), 107-114
- https://doi.org/10.1016/j.pupt.2009.10.009
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- ACCELERATED DOSING FREQUENCY OF A PULMONARY FORMULATION OF TISSUE PLASMINOGEN ACTIVATOR IS WELL‐TOLERATED IN MICEClinical and Experimental Pharmacology and Physiology, 2008
- Utility of magnetic resonance imaging and nuclear magnetic resonance-based metabolomics for quantification of inflammatory lung injuryAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2008
- Oxidative Stress, Plasminogen Activator Inhibitor 1, and Lung FibrosisAntioxidants and Redox Signaling, 2008
- The Role of Inflammation in the Pathogenesis of Idiopathic Pulmonary FibrosisAntioxidants and Redox Signaling, 2008
- Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injuryCritical Care, 2008
- Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008Critical Care Medicine, 2007
- Emerging Role of Anticoagulants and Fibrinolytics in the Treatment of Acute Respiratory Distress SyndromePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007
- Immunogenicity of Tissue Plasminogen Activators in Rhesus Monkeys: Antibody Formation and Effects on Blood Level and Enzymatic ActivityFundamental and Applied Toxicology, 1996
- Characterization of the Murine Plasma Fibrinolytic SystemEuropean Journal of Biochemistry, 1994
- Tissue Plasminogen ActivatorNew England Journal of Medicine, 1988